Study details
Enrolling now
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT IDNCT06503146ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
320
Study length
about 4.7 years
Ages
18–120
Locations
1 site in MD
What this study is about
Researchers are testing whether a new imaging test, using the substance [18F]FAPI-74, can help find certain types of cancer. The trial will compare this new test to another approved test called [18F]-FDG. Participants with specific cancers like pancreatic or lung cancer may be eligible.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take [18F]FAPI-74
- 2.Take [18F]FDG
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Safety of [18F]FAPI 74 PET imaging
Body systems
Oncology